EICHORCondition: Advanced or Metastatic Solid Tumors · Sponsor: PharmAbcine
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety, tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in participants with advanced or metastatic solid tumors administered as a monotherapy and in combination with pembrolizumab.
This description comes directly from the study's public registry record.
Hyojin Koh, Dr · 070-4213-2925 · hyojin.koh@pharmabcine.com
Always discuss trial participation with your own doctor first.
| Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital | Benowa, Queensland, Australia | Recruiting |
| Ballarat Regional Integrated Cancer Centre (Grampians Health) | Ballarat, Victoria, Australia | Recruiting |
| Cabrini Health Limited | Malvern, Victoria, Australia | Recruiting |
| Alfred Health | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05957081